Table 1

Baseline characteristics of the 36 SLE subjects

Age34±12 (19–67)
EthnicityAfrican-American 8, Asian 8, Caucasian 5, Hispanic 13, other 2
Years since diagnosis (years)8±10 (0–35)
SELENA-SLEDAI score8±5 (4–27)
BILAG-2004 index score15±10 (1–48)
uPCR (>0.5 g/g)47.2%
Positive ANA ≥20 units97.2%
Positive anti-dsDNA (>301 units)64%
EC4d (net MFI)52±11 (8–719)
EC3d (net MFI)14±55 (<1–333)
ECR1 (net MFI)13±6 (2–24)
C3 levels (mg/dL)76±32 (20–145)
C4 levels (mg/dL)15±7 (4–44)
Low complement*72%
Elevated CB-CAPs100%
Anti-C1q positive (>20 units)64%
  • Results are expressed as mean±SD (range).

  • *Low complement was defined as either C3 or C4 levels below the normal range established at each of the sites.

  • BILAG, British Isles Lupus Assessment Group; CB-CAPs, cell-bound complement activation products; MFI, mean fluorescent intensity; SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus: National Assessment; SLE, systemic lupus erythematosus; uPCR, urinary protein to creatinine ratio.